Last Updated : November 11, 2016
Details
FilesGeneric Name:
Carfilzomib (with lenalidomide)
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma
Manufacturer:
Amgen Canada Inc.
Brand Name:
Kyprolis (with lenalidomide)
Project Line:
Reimbursement Review
Project Number:
PC0067-000
NOC Status at Filing:
Pre NOC
Strength:
60 mg vial
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
In combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma following one prior treatment failure
Pre Noc Submission:
Yes
Sponsor:
Amgen Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
The pERC Final Recommendation posted on June 21, 2016 was revised on November 11, 2016 in order to align the patient population in the pERC Recommendation with the pivotal trial (ASPIRE). The pCODR Provincial Advisory Group has been notified of this revision.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Clarification:
The pERC Final Recommendation posted on June 21, 2016 was revised on November 11, 2016 in order to align the patient population in the pERC Recommendation with the pivotal trial (ASPIRE). The pCODR Provincial Advisory Group has been notified of this revision.
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : November 11, 2016